PharmaEngine Receives $1.5M Milestone as ONIVYDE® 1L Pancreatic Cancer Filing is Accepted in Japan

PharmaEngine (智擎) started 2026 with a regulatory milestone, announcing that its sublicense partner, Servier, has had its supplemental New Drug Application (sNDA) for ONIVYDE® as a first-line (1L) combination therapy for metastatic pancreatic ductal adenocarcinoma (PDAC) accepted by Japan's PMDA.